Eli Lilly is a safer way to capitalize on AI-driven drug discovery.
RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the 12 Best Genomics Stocks to Invest In. Cathie Wood’s ARK Investment ...
Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...
On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...
Before market open, Recursion divulged that its REC-4881 demonstrated notable efficacy in a phase 1b/2 trial. The drug, which treats a disorder called familial adenomatous polyposis (FAP) in which ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
Photo of Najat Khan, Ph.D. Najat Khan, Ph.D. SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to ...
We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback